OpenAI 收购 Orchestra Bio 强化生物科技业务
原标题：OpenAI acquires startup Orchestra Bio to beef up its biotech business
AI 摘要
OpenAI 宣布收购成立四年的 AI 生物科技软件初创公司 Orchestra Bio，交易金额未披露，该公司截至 2025 年已融资约 2000 万美元。Orchestra 开发 AI agent，帮助生物科技公司处理药物研发运营中的琐碎事务，如财务追踪和临床试验排期。OpenAI 将把 Orchestra 的团队与技术并入其生命科学研究模型 Rosalind 及 Rosalind Workbench 工具，Rosalind 已获得 Moderna、Novo Nordisk 等客户。
正文节选
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC. Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials. OpenAI says it’s adding O